Welcome To Stuart Therapeutics
Stuart Therapeutics, established in 2017 is developing PolyCol, a unique therapeutic platform that has shown promise as a direct tissue reparative for collagen membranes and structures in the eye. PolyCol’s unique method of action results in accelerated healing and recovery in various ophthalmic disease states and offers a new way to address indications such as dry eye disease, dry age related macular degeneration and glaucoma.
PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property acquired by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.
Stuart’s first drug candidate based on the PolyCol platform, ST-100, is an extremely fast acting therapeutic that directly addresses the corneal tissue damage associated with dry eye disease. For a look at our non-confidential summary presentation, please click here.
Stuart Therapeutics’ first drug candidate is ST-100, a novel therapeutic in drop formulation for Dry Eye Disease (DED). Unlike most therapeutic solutions for DED, ST-100 is a fast acting, broadly applicable option for patients that has shown an ability to provide complete corneal healing in less than 24 hours in animal studies. ST-100 is believed to act by directly healing and aligning exposed and damaged collagen fibers in moderate to severe DED sufferers, providing an ideal environment for epithelial recovery and relief from painful symptoms.
Stuart Therapeutics, Inc. Announces Pro-Neuronal Growth Results Using PolyColTM Collagen Mimetic Peptides
STUART, FLORIDA November 11th, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has successfully completed in vitro pro-neuronal growth experiments utilizing the company’s PolyColTM (PolyCol) peptide. PolyCol demonstrated a strong propensity to encourage neurite outgrowth from dorsal root ganglia nerve cells in a model designed to mirror damage
STUART, FLORIDA June 12, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical ophthalmic therapeutic development company, today announces it has entered into a strategic partnership with Ora®, Inc. (“ORA”), the premier global ophthalmology contract research organization. ORA is investing in its partnership with STUART by providing CMC program execution, IND preparation, and related strategic consulting
April 22nd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD).